Evidence map›Paper›PMID 35459777›Full record

ArticleScientific reports2022

Automated quantitative high-throughput multiplex immunofluorescence pipeline to evaluate OXPHOS defects in formalin-fixed human prostate tissue.

Ashwin Sachdeva, Claire A Hart, Christopher D Carey, Amy E Vincent, Laura C Greaves, Rakesh Heer, Pedro Oliveira, Michael D Brown, Noel W Clarke, Doug M Turnbull

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Label-free optical biomarker for prostate cancer diagnosis.Molecular medicine (Cambridge, Mass.) · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Ashwin SachdevaGenito Urinary Cancer Research Group, Division of Cancer Sciences, Oglesby Cancer Research Building, University of Manchester, Manchester, M20 4GJ, UK. ashwin.sachdeva@nhs.net.
Claire A HartGenito Urinary Cancer Research Group, Division of Cancer Sciences, Oglesby Cancer Research Building, University of Manchester, Manchester, M20 4GJ, UK.
Christopher D CareyTranslational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
Amy E VincentWellcome Centre for Mitochondrial Research, Newcastle University, Newcastle-upon-Tyne, UK.
Laura C GreavesWellcome Centre for Mitochondrial Research, Newcastle University, Newcastle-upon-Tyne, UK.
Rakesh HeerTranslational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
Pedro OliveiraDepartment of Pathology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.
Michael D BrownGenito Urinary Cancer Research Group, Division of Cancer Sciences, Oglesby Cancer Research Building, University of Manchester, Manchester, M20 4GJ, UK.
Noel W ClarkeGenito Urinary Cancer Research Group, Division of Cancer Sciences, Oglesby Cancer Research Building, University of Manchester, Manchester, M20 4GJ, UK.
Doug M TurnbullWellcome Centre for Mitochondrial Research, Newcastle University, Newcastle-upon-Tyne, UK.
Newcastle University · GBWellcome Centre for Mitochondrial Research · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBProstate Cancer UK · GBSalford Royal NHS Foundation Trust · GBThe Christie NHS Foundation Trust · GBUniversity of Manchester · GB

Funding

Cancer Research UK 19427Department of HealthWellcome Trust 215888/Z/19/Z
6 · The paper itself

Abstract

Advances in multiplex immunofluorescence (mIF) and digital image analysis has enabled simultaneous assessment of protein defects in electron transport chain components. However, current manual methodology is time consuming and labour intensive. Therefore, we developed an automated high-throughput mIF workflow for quantitative single-cell level assessment of formalin fixed paraffin embedded tissue (FFPE), leveraging tyramide signal amplification on a Ventana Ultra platform coupled with automated multispectral imaging on a Vectra 3 platform. Utilising this protocol, we assessed the mitochondrial oxidative phosphorylation (OXPHOS) protein alterations in a cohort of benign and malignant prostate samples. Mitochondrial OXPHOS plays a critical role in cell metabolism, and OXPHOS perturbation is implicated in carcinogenesis. Marked inter-patient, intra-patient and spatial cellular heterogeneity in OXPHOS protein abundance was observed. We noted frequent Complex IV loss in benign prostate tissue and Complex I loss in age matched prostate cancer tissues. Malignant regions within prostate cancer samples more frequently contained cells with low Complex I & IV and high mitochondrial mass in comparison to benign-adjacent regions. This methodology can now be applied more widely to study the frequency and distribution of OXPHOS alterations in formalin-fixed tissues, and their impact on long-term clinical outcomes.

Indexed as

Fluorescent Antibody TechniqueProstateProstatic NeoplasmsElectron Transport Complex IVFormaldehydeHumansMaleOxidative PhosphorylationParaffin EmbeddingTissue FixationElectron Transport Complex IVFormaldehyde

Identifiers

PMID35459777
PMCPMC9033818
OpenAlexW4224229139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.